Advaxis (NASDAQ:ADXS) Trading 6.3% Higher

Advaxis, Inc. (NASDAQ:ADXS) shares traded up 6.3% on Friday . The stock traded as high as $0.35 and last traded at $0.34, 3,792,469 shares were traded during trading. An increase of 90% from the average session volume of 1,998,121 shares. The stock had previously closed at $0.32.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Advaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th. ValuEngine upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The company’s 50-day moving average price is $0.31 and its two-hundred day moving average price is $1.39. The company has a market capitalization of $5.58 million, a price-to-earnings ratio of -0.02 and a beta of 3.21.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, September 9th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.24. Advaxis had a negative net margin of 113.67% and a negative return on equity of 67.08%. The company had revenue of $0.01 million for the quarter. Analysts predict that Advaxis, Inc. will post -2.7 earnings per share for the current fiscal year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. JPMorgan Chase & Co. lifted its position in shares of Advaxis by 53,633.7% during the second quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 50,952 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Advaxis by 71.1% during the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock valued at $481,000 after purchasing an additional 95,607 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Advaxis by 143.7% during the second quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after buying an additional 295,444 shares during the last quarter. 7.32% of the stock is currently owned by institutional investors.

Advaxis Company Profile (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Read More: Asset Allocation

Leave a Reply

Your email address will not be published. Required fields are marked *

*